Back to Journals » OncoTargets and Therapy » Volume 10

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation

Authors Zeng D, Wang C, Huang J, Jiang J

Received 12 April 2017

Accepted for publication 21 June 2017

Published 28 August 2017 Volume 2017:10 Pages 4269—4272


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Ingrid Espinoza

Da-xiong Zeng,* Chang-guo Wang,* Jian-an Huang, Jun-hong Jiang

Department of Respiratory and Critical Care, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China

*These authors contributed equally to this work

Abstract: Activating KRAS mutations in lung adenocarcinoma are characterized with treatment resistance and poor prognosis. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase, apatinib has been proven successful in advanced gastric cancer and breast cancer. In this study, we show the result of apatinib as salvage treatment in lung adenocarcinoma patients with KRAS mutation. Four advanced lung adenocarcinoma patients with KRAS mutation were orally administered apatinib (250 mg/d) after second-line treatment. One patient showed progressive disease, while 3 patients showed stable disease response to apatinib, with a median progression-free survival (PFS) of 3.8 months (1.5–5.5 months). The main toxicities were hoarseness and hemoptysis, which were manageable. Therefore, apatinib might be an optional choice for advanced lung adenocarcinoma patients with KRAS mutation in post second-line treatment.

Keywords: lung cancer, apatinib, VEGFR-2, KRAS mutation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]